Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M

Aclaris Therapeutics, Inc.

2023-FY EPS reported -$1.27 revenue$31,249,000

Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.
Full-year net loss $88.5M; cash & securities $181.9M (Dec 2023) vs $229.8M (Dec 2022).
Impairment charge of $6.6M on IPR&D asset after discontinuing an immuno-inflammatory drug candidate.
Positive Phase 2b top-line for ATI-1777 in atopic dermatitis; seeking a partner for development/commercialization.
Co-founder Dr. Neal Walker returns as Interim CEO; company to advance zunsemetinib in oncology via Washington University trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aclaris Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022., net income Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N.

Period: fourth quarter and full year ended December 31, 2023
Revenue: Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022.
Net income: Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N
Result: reported results

Exact text from the filing

Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2023

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-001752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.